Capricor Therapeutics Inc (NASDAQ: CAPR) has found that its study on CAP-1002 is safe. This announcement comes after a Phase II trial to evaluate an intravenous dose of the drug. CAP-1002 treats patients with severe cases of COVID-19.
The company tested the drug on patients with severe COVID-19
The company conducted the study on 63 patients, 31% of whom were in the ICU for advanced COVID-19 before the treatment began. Moreover, 82% of the participants had severe COVID-19 as per the WHO ordinal classification.
As per Capricor’s CEO, Linda Marbán, CAP-1002 was suitably tolerated in the patients despite severe disease cases. He adds that the company will decide on its next steps as more people in the U.S receive vaccination and mortality goes down. The company will take time to examine this data. However, it is open to any offers for partnerships that could come.
Capricor tested CAP-1002 in the INSPIRE study, a placebo-controlled, double-blind, randomized study. It investigated people with a positive clinical COVID-19 diagnosis. The patients were also in critical condition and required supplemental oxygen.
Capricor conducted the trial to determine if administering a single drug dose intravenously was safe. It also wanted to gauge the efficacy of CAP-1002. They administered the compound to patients and assessed them for 90 days.
CAP-1002 has been part of several trials
Scientists previously found CAP-1002 to have strong immunomodulatory activity. It can alter the action of the immune system and promote cell regeneration. The compound has been in more than 100 reputable scientific publications. Researchers have also given it to more than 200 people in different clinical trials.
Capricor Therapeutics is a company that focuses on developing exosome-based and transformative cell vaccines and therapeutics for various diseases. Among its top priority projects is CAP-1002.
CAP-1002 has the potential to treat COVID-19 and Duchenne muscular dystrophy. This genetic disorder is characterized by gradual muscle weakness. It primarily affects young men and boys, while girls are generally carriers or have mild disease cases. The company is also creating an exosome-based technology therapeutic platform. Currently, the company is developing exosomes that can deliver nucleic acids, proteins, and mRNA to treat diseases.
